ClinicalTrials.gg
CompletedNCT01728077Updated Jul 11, 2018Results posted

Evaluation of Long-term Safety, and Efficacy of Brivaracetam (BRV) Used as Adjunctive Treatment in Subjects With Epilepsy

A Phase 3 interventional study of Brivaracetam in Epilepsy, sponsored by UCB Pharma SA. Completed at 10 sites in 4 countries. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2018-07-11.

Sponsored by UCB Pharma SA (part of UCB S.A.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
26
Allocation
Not applicable
Ages
16 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 34 studies testing brivaracetam in Epilepsy — 2 open to participants now, 2 under way, 1 of them phase 3. brivaracetam · Epilepsy.

Enrollment
26th of 34
26 · median 94
Started
2012
with 1 other
Phase 3
21 of 34
1 open now
Registered
20th of 34
by date
Lead sponsor
5 of 34
UCB Pharma SA

Among the 34 studies testing brivaracetam in Epilepsy, this one is the 26th largest by enrollment, is one of 2 that started in 2012, is one of 21 in phase 3, and was the 20th registered.

Epilepsy

1,848 studies on the registry are indexed under Epilepsy; 419 are open to participants now.

Browse Epilepsy studies →

Open to participants now

2 of the 34 studies testing brivaracetam in Epilepsy are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About brivaracetam

brivaracetam: first FDA approval 2016 (BRIVIACT), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 284 Epilepsy studies recruiting now, 114 (40%) set no upper age limit and 147 (52%) stop at 75 or younger; 139 take children under 18; 55 take healthy volunteers.

This study: 16 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies testing brivaracetam in Epilepsy, or all of them as a file.
02

Study summary

N01372 study is to evaluate the long-term safety, tolerability, maintenance of efficacy of Brivaracetam (BRV); as well as the effect of BRV on subjects' health-related quality of life and to explore the direct medical resource use for BRV (for subjects entering N01372 from a study where pharmacoeconomic data was collected). BRV will be used at doses up to maximum of 200 mg/day, as adjunctive treatment in subjects aged 16 years or older with Epilepsy.

Read the detailed description

Flexible dosing up to 200 mg/day, twice daily (10, 25 and 50 mg oral film-coated tablets). The study will continue until either regulatory approval of BRV has been granted by any Health Authority in an indication of adjunctive treatment of Epilepsy, or until the Sponsor decides to close the study, or until the BRV development is stopped by the Sponsor.

03

Conditions studied

  • Epilepsy

Browse trials for

Keywords

  • Brivaracetam
  • Long-term Follow-up
  • Epilepsy
  • Partial Onset Seizures
  • Adjunctive treatment
04

Who can participate

Ages eligible
16 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject is male or female and 16 years or older. Subjects under 18 years of age may be included only where legally permitted and ethically accepted
  • Subjects having completed the Treatment Period of an applicable previous BRV study, and have access to the present study
  • Subject for whom the investigator believes a reasonable benefit from the long-term administration of BRV may be expected
  • Female subjects without ( for at least 2 years, bilateral oophorectomy or tubal ligation, complete hysterectomy) are eligible. Female subjects with childbearing potential are eligible if they use a medically accepted method
  • Subjects must be able to take the oral film-coated tablets of BRV

Exclusion criteria

Exclusion Criteria:

  • Subject has developed to any components of the Medicinal Product (IMP) or comparative drugs as stated in the protocol during the course of the prior study
  • Severe medical, neurological, or psychiatric disorders, or laboratory values that may have an impact on the safety of the subject
  • Poor compliance with the visit schedule or medication intake in the previous BRV study
  • Planned participation in any other clinical study of another investigational drug or device during this study
  • Pregnant or lactating woman
  • Any medical condition which, in the investigator's opinion, warrants exclusion
  • Subject has a lifetime history of suicide attempt (including an actual attempt, interrupted attempt, or aborted attempt), or has suicidal ideation in the past 6 months as indicated by a positive response ("Yes") to either question 4 or question 5 of the Columbia-Suicide Severity Rating Scale (C-SSRS) at the last visit of the previous study or at the Entry Visit of this study if not completed at the last visit of the previous study
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
26 participants (actual)

Study arms

  • Experimental
    Brivaracetam

    At Entry Visit (EV), subjects will start on the individualized Brivaracetam (BRV) dose that they had reached at the completion of the previous study. Dose adjustments of the Investigational Medicinal Product (IMP) are allowed at any time based on the clinical judgment of the investigator. The BRV dose can be increased or decreased in increments of 50 mg/day based on the individual subject's seizure control and/or tolerability; however, the BRV dose should not exceed 200 mg/day during the study and must always be administered as a symmetrical morning and evening dose. Upon completion or early discontinuation from this study, there will be a Down-Titration Period in steps of 50 mg/day on a weekly basis until 20 mg/day for 1 week is reached, followed by a Post-Treatment Period (between 2 and 4 weeks) during which the subject will not receive study drug. No down-Titration Period will be applicable if subjects are continued on BRV after they complete this study.

    Drug: Brivaracetam

Interventions

  • Flexible dosing, can up and down-titrate as needed.

    Also known as: UCB34714

06

What researchers measure

Primary outcomes

  1. Incidence of Treatment Emergent Adverse Events (TEAEs) During Evaluation Period

    TEAEs were defined as AEs that had onset on or after the day of first study medication dose. An AE is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product that does not necessarily have a causal relationship with this treatment. Results are presented as the percentage of subjects with at least one treatment-emergent adverse event during this study.

    Time frame: From Entry Visit (Month 0) to the Last Evaluation Period Visit or Early Discontinuation Visit (up to 46 months)

  2. Percentage of Subjects Withdrawn Due to an Adverse Event (AE) During the Evaluation Period

    An AE was defined as any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product that did not necessarily have a causal relationship with this treatment. Results are presented as the percentage of subjects withdrawn due to an AE.

    Time frame: From Entry Visit (Month 0) to the Last Evaluation Period Visit or Early Discontinuation Visit (up to 46 months)

  3. Occurrence of a Serious Adverse Event (SAE) During the Evaluation Period

    SAEs include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity or are a congenital anomaly/birth defects. Results are presented as the percentage of subjects with at least one SAE during this study.

    Time frame: From Entry Visit (Month 0) to the Last Evaluation Period Visit or Early Discontinuation Visit (up to 46 months)

Secondary outcomes

  1. Frequency of Partial-Onset Seizure (POS) Type I Per 28 Days During the Evaluation Period for Subjects With Focal-onset Epilepsy

    The POS frequency is standardized to a 28-day duration. Results are presented as the median number of seizures per 28 days.

    Time frame: From Entry Visit (Month 0) to the Last Evaluation Period Visit or Early Discontinuation Visit (up to 46 months)

  2. Percentage of Change in Partial-Onset-Seizure (POS) Type I Frequency Per 28 Days From Baseline of the Previous Study to the Evaluation Period for Subjects With Focal-onset Epilepsy Entering N01372 From a Study Where Baseline Seizure Data Was Collected

    The POS frequency is standardized to a 28-day duration. Results are presented as the median percentage of reduction per 28 days. Negative values indicate improvement from Baseline.

    Time frame: From Baseline of the previous study to the Last Evaluation Period Visit or Early Discontinuation Visit (up to 49 months)

  3. 50 % Responder Rate in Partial-Onset-Seizure (POS) Type I Frequency From Baseline of the Previous Study to the Evaluation Period for Subjects With Focal-onset Epilepsy Entering N01372 From a Study Where Baseline Seizure Data Was Collected

    The POS frequency is standardized to a 28-day duration. A responder is defined as a subject with a \>=50% reduction in seizure frequency from the Baseline Period of the previous study. Results are presented as the percentage of subjects with 50 % responder rate in POS Type I frequency.

    Time frame: From Baseline of the previous study to the Last Evaluation Period Visit or Early Discontinuation Visit (up to 49 months)

07

Results

Posted Aug 2, 2017

Participant flow

This study started to enroll subjects in October 2012 and concluded in August 2016.

Participant flow — Overall Study
MilestoneBrivaracetam Focal EpilepsyBrivaracetam Generalized Epilepsy
Started197
Completed112
Not completed85
Withdrew: Lack of efficacy31
Withdrew: Lost to follow-up10
Withdrew: Subject choice23
Withdrew: Death01
Withdrew: Patient moving10
Withdrew: Non compliance10

Outcome measures

PrimaryIncidence of Treatment Emergent Adverse Events (TEAEs) During Evaluation Period

TEAEs were defined as AEs that had onset on or after the day of first study medication dose. An AE is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product that does not necessarily have a causal relationship with this treatment. Results are presented as the percentage of subjects with at least one treatment-emergent adverse event during this study.

Time frame:
From Entry Visit (Month 0) to the Last Evaluation Period Visit or Early Discontinuation Visit (up to 46 months)
Reported as:
Number · percentage of subjects
Incidence of Treatment Emergent Adverse Events (TEAEs) During Evaluation Period
percentage of subjectsBrivaracetam Focal Epilepsy (SS)Brivaracetam Generalized Epilepsy (SS)
Incidence of Treatment Emergent Adverse Events (TEAEs) During Evaluation Period78.971.4
PrimaryPercentage of Subjects Withdrawn Due to an Adverse Event (AE) During the Evaluation Period

An AE was defined as any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product that did not necessarily have a causal relationship with this treatment. Results are presented as the percentage of subjects withdrawn due to an AE.

Time frame:
From Entry Visit (Month 0) to the Last Evaluation Period Visit or Early Discontinuation Visit (up to 46 months)
Reported as:
Number · percentage of subjects
Percentage of Subjects Withdrawn Due to an Adverse Event (AE) During the Evaluation Period
percentage of subjectsBrivaracetam Focal Epilepsy (SS)Brivaracetam Generalized Epilepsy (SS)
Percentage of Subjects Withdrawn Due to an Adverse Event (AE) During the Evaluation Period014.3
PrimaryOccurrence of a Serious Adverse Event (SAE) During the Evaluation Period

SAEs include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity or are a congenital anomaly/birth defects. Results are presented as the percentage of subjects with at least one SAE during this study.

Time frame:
From Entry Visit (Month 0) to the Last Evaluation Period Visit or Early Discontinuation Visit (up to 46 months)
Reported as:
Number · percentage of subjects
Occurrence of a Serious Adverse Event (SAE) During the Evaluation Period
percentage of subjectsBrivaracetam Focal Epilepsy (SS)Brivaracetam Generalized Epilepsy (SS)
Occurrence of a Serious Adverse Event (SAE) During the Evaluation Period26.328.6
SecondaryFrequency of Partial-Onset Seizure (POS) Type I Per 28 Days During the Evaluation Period for Subjects With Focal-onset Epilepsy

The POS frequency is standardized to a 28-day duration. Results are presented as the median number of seizures per 28 days.

Time frame:
From Entry Visit (Month 0) to the Last Evaluation Period Visit or Early Discontinuation Visit (up to 46 months)
Reported as:
Median · Seizures per 28 days
Frequency of Partial-Onset Seizure (POS) Type I Per 28 Days During the Evaluation Period for Subjects With Focal-onset Epilepsy
Seizures per 28 daysBrivaracetam Focal Epilepsy (EAS)
Frequency of Partial-Onset Seizure (POS) Type I Per 28 Days During the Evaluation Period for Subjects With Focal-onset Epilepsy0.4 (0 to 124)
SecondaryPercentage of Change in Partial-Onset-Seizure (POS) Type I Frequency Per 28 Days From Baseline of the Previous Study to the Evaluation Period for Subjects With Focal-onset Epilepsy Entering N01372 From a Study Where Baseline Seizure Data Was Collected

The POS frequency is standardized to a 28-day duration. Results are presented as the median percentage of reduction per 28 days. Negative values indicate improvement from Baseline.

Time frame:
From Baseline of the previous study to the Last Evaluation Period Visit or Early Discontinuation Visit (up to 49 months)
Reported as:
Median · percentage of change
Percentage of Change in Partial-Onset-Seizure (POS) Type I Frequency Per 28 Days From Baseline of the Previous Study to the Evaluation Period for Subjects With Focal-onset Epilepsy Entering N01372 From a Study Where Baseline Seizure Data Was Collected
percentage of changeBrivaracetam Focal Epilepsy (EAS)
Percentage of Change in Partial-Onset-Seizure (POS) Type I Frequency Per 28 Days From Baseline of the Previous Study to the Evaluation Period for Subjects With Focal-onset Epilepsy Entering N01372 From a Study Where Baseline Seizure Data Was Collected-56.3 (-97 to 717)
Secondary50 % Responder Rate in Partial-Onset-Seizure (POS) Type I Frequency From Baseline of the Previous Study to the Evaluation Period for Subjects With Focal-onset Epilepsy Entering N01372 From a Study Where Baseline Seizure Data Was Collected

The POS frequency is standardized to a 28-day duration. A responder is defined as a subject with a \>=50% reduction in seizure frequency from the Baseline Period of the previous study. Results are presented as the percentage of subjects with 50 % responder rate in POS Type I frequency.

Time frame:
From Baseline of the previous study to the Last Evaluation Period Visit or Early Discontinuation Visit (up to 49 months)
Reported as:
Number · percentage of subjects
50 % Responder Rate in Partial-Onset-Seizure (POS) Type I Frequency From Baseline of the Previous Study to the Evaluation Period for Subjects With Focal-onset Epilepsy Entering N01372 From a Study Where Baseline Seizure Data Was Collected
percentage of subjectsBrivaracetam Focal Epilepsy (EAS)
50 % Responder Rate in Partial-Onset-Seizure (POS) Type I Frequency From Baseline of the Previous Study to the Evaluation Period for Subjects With Focal-onset Epilepsy Entering N01372 From a Study Where Baseline Seizure Data Was Collected54.5

Adverse events

Collected over Adverse events collection started at Day 0 and continued up to 30 days after last intake of study medication.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Brivaracetam Focal Epilepsy (SS)—5/19 (26.3%)13/19 (68.4%)
Brivaracetam Generalized Epilepsy (SS)—2/7 (28.6%)5/7 (71.4%)
Most frequent serious events
Showing 10 of 15
Most frequent serious events
EventBrivaracetam Focal Epilepsy (SS)Brivaracetam Generalized Epilepsy (SS)
Cardio-respiratory arrestCardiac disorders0/191/7
DrowningGeneral disorders0/191/7
Status epilepticusNervous system disorders1/191/7
ConvulsionNervous system disorders2/190/7
LeukocytosisBlood and lymphatic system disorders1/190/7
Myocardial infarctionCardiac disorders1/190/7
Chest painGeneral disorders1/190/7
PneumoniaInfections and infestations1/190/7
SepsisInfections and infestations1/190/7
HypomagnesaemiaMetabolism and nutrition disorders1/190/7
Most frequent other events
Showing 10 of 25
Most frequent other events
EventBrivaracetam Focal Epilepsy (SS)Brivaracetam Generalized Epilepsy (SS)
HeadacheNervous system disorders7/191/7
Urinary tract infectionInfections and infestations2/192/7
Upper respiratory tractInfections and infestations1/192/7
FatigueGeneral disorders3/190/7
Back painMusculoskeletal and connective tissue disorders3/191/7
ConvulsionNervous system disorders3/190/7
DizzinessNervous system disorders3/190/7
NauseaGastrointestinal disorders2/191/7
DiarrhoeaGastrointestinal disorders1/191/7
VomitingGastrointestinal disorders1/191/7

Baseline characteristics

Baseline Characteristics refer to the Safety Set, which consisted of all subjects who received at least 1 dose of study medication.

Age, Categorical
Age, Categorical(Participants)Brivaracetam Focal EpilepsyBrivaracetam Generalized EpilepsyTotal Title
<=18 years000
Between 18 and 65 years19726
>=65 years000
Age, Continuous
Age, Continuous(years)Brivaracetam Focal EpilepsyBrivaracetam Generalized EpilepsyTotal Title
Arithmetic mean (standard deviation)38.6 ± 10.930.7 ± 13.236.5 ± 11.9
Sex: Female, Male
Sex: Female, Male(Participants)Brivaracetam Focal EpilepsyBrivaracetam Generalized EpilepsyTotal Title
Female7512
Male12214
08

Study locations

10 sites
  • 103
    Little Rock, Arkansas, United States
  • 108
    Lexington, Kentucky, United States
  • 109
    New York, New York, United States
  • 106
    Akron, Ohio, United States
  • 110
    Dallas, Texas, United States
  • 102
    Salt Lake City, Utah, United States
  • 201
    Paris, France
  • 303
    Bernau, Germany
  • 300
    Kehl-Kork, Germany
  • 502
    Sevilla, Spain
09

References and documents

Publications

  • Markham A. Brivaracetam: First Global Approval. Drugs. 2016 Mar;76(4):517-22. doi: 10.1007/s40265-016-0555-6. PubMed 26899665 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2012, a primary completion of Aug 2016 and a completion of Aug 2016. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2017, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 26, 2012
First posted
Nov 16, 2012
Start
Oct 2012
Primary completionActual
Aug 2016
CompletionActual
Aug 2016
Results first posted
Aug 2, 2017
Last update
Jul 11, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 11, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01728077
Lead sponsor
UCB Pharma SA
Responsible party
Sponsor
First posted
Nov 16, 2012
Start date
Oct 2012
Primary completion
Aug 2016
Completion
Aug 2016
Results posted
Aug 2, 2017
Last update
Jul 11, 2018

Study contacts

UCB Cares
study director · +1 877 822 9493 (UCB)

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Brivaracetam

Start the discussion